Benefit of Hard Endpoints With Complete Revascularization in Acute MI | Results From IPD Meta-Analysis of 6 RCT's

Sunday, March 8, 2026

4:47 PM - 4:55 PM EST

Location: Lincoln

Speaker(s)

Pieter C. Smits, PhD, FESC

Chief Medical Director
CERC (Cardiovascular European Research Center)
Rotterdam, Zuid-Holland, Netherlands

Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Terminated, October 1, 2025), Grant/Research Support (Terminated, October 1, 2025); CERC ( centre european of cardiovascular research): Employee (Ongoing), Stock-privately held company (Ongoing); MicroPort Medical: Consulting Fees (e.g., advisory boards) (Ongoing); SMT: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 1, 2025)

Disclosure(s):

Pieter C. Smits, PhD, FESC: Abbott Vascular: Consulting Fees (e.g., advisory boards) (Terminated, October 1, 2025), Grant/Research Support (Terminated, October 1, 2025); CERC ( centre european of cardiovascular research): Employee (Ongoing), Stock-privately held company (Ongoing); MicroPort Medical: Consulting Fees (e.g., advisory boards) (Ongoing); SMT: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 1, 2025)